

Aneurysm/AVM/cSDH Roundtable Discussion with Industry and Stroke Experts

05/25-26 2023

ARLINGTON VA. USA





New Perspectives on Epidemiology, Clinical Trials, Patient Selection, Evolving Therapies and Pre-clinical System Models











Mission:

The ARISE Consensus Conferences, via a collaboration of medical academia, the healthcare industry and government agencies, are intended to advance and accelerate research in the treatment of brain aneurysms (IA), arteriovenous malformations (bAVM), and chronic subdural hematomas (cSDH), to ultimately result in improved acute and elective management, treatment, and prevention. To achieve this goal, ARISE 2023 will:

- **↓** Develop new approaches to overcome barriers impeding drug and device development
- **♣** Publish the consensus recommendations of ARISE participants which address these concerns
- ♣ Promote adoption of ARISE solutions by research, industry, clinical and government communities

Who is involved:

ARISE architecture thus includes 3 major stakeholders research and practice in the treatment of brain aneurysms, brain arteriovenous malformations and chronic subdural hematomas: academia (leading international physicians/scientists from all involved disciplines), industry (scientists and executives from private sector pharmaceutical, device, and imaging companies), and regulatory institutions (executive managers, physicians and scientists from NIH and FDA).

Preliminary Agenda:

ARISE starts with a one full day meeting focusing on cutting-edge clinical and research study designs, analytic methods, novel drugs/devices, biomarkers, and outcomes. The specific sessions included in the program are:

SESSION 1: BRAIN ANEURYSMS - NEW DATA, NEW LANDSCAPE, NEW APROACHES

SESSION 2: cSDH: NEW DATA, NEW LANDSCAPE, NEW APROACHES

SESSION 3: bAVM: NEW DATA, NEW LANDSCAPE, NEW APROACHES

SESSION 4: REGULATORY PERSPECTIVE ON KEY CLINICAL TRIAL ISSUES

The second day of the ARISE is focused on the consensus process to develop recommendations. Participating experts from academia, industry and regulatory institutions are divided into 2 groups for preparation of the consensus recommendations. They are provided equal opportunity to contribute to a facilitated discussion process, during which recommendations developed by leading academic thought leaders in aneurysms, bAVM and cSDH are presented, openly discussed, and may be amended, expanded, replaced, and refined by the group. Each of the 2 content groups then present their recommendations to the entire assembly. Writing committees draft the manuscripts for review of the group and the resulting articles are then published.

Second Day Workshops (2 groups)

WORKSHOP 1: MOST PROMISING APPROACHES TO IMPROVE BRAIN ANEURYSM OUTCOMES WORKSHOP 2: MOST PROMISING APPROACHES TO IMPROVE BRAIN AVM and cSDH OUTCOMES



Workshop Chairs Present Recommendations to Full Assembly Drafting of consensus statement is initiated Closing Comments and Adjournment

CORE ORGANISERS:



Prof Ajay K. Wakhloo, MD PhD FAHA FSNIS
Professor TUFTS University School of Medicine, Beth
Israel LAHEY Health, LAHEY Hospital & Medical
Center



Prof Adam S. Arthur, MD MPH FAANS FSNIS Professor and chair of Neurosurgery at University of Tennessee Health Science Center (UTHSC)

Invitation:

ARISE is a Roundtable where only invited faculty and companies can participate. The goal is to have companies from different fields involved.

ARISE is then *inviting* your company to participate in this meeting by supporting this excellent platform that has a goal to foster consensus in areas of major relevance to ARISE and the networks needed to design/conduct successful trials in the field.

You have the possibility to bring your company's representatives, according to your support level. Please contact us to discuss the possibilities.

FOR FURTHER DETAILS, PLEASE CONTACT ME:



BILYANA HRISTOVA Industry Liaison & Sales Associate E: <u>bhristova@kenes.com</u> | T: +41 22 908 0488 Ext. 214

Funding:

Please note, ARISE does not receive any government funding. ARISE conferences are funded solely by participating private sector companies.

